Immunic reports FY2023 net loss of $93.6M; raises $80M in Jan 2024 private placement

IMMUNIC, INC.

2023-FY EPS reported -$2.11

Net loss for FY2023: $93.6M ($2.11 per share) vs $120.4M ($3.78 per share) in FY2022.
Cash as of Dec 31, 2023: $46.7M; extended to Q3 2025 after $80M Jan 2024 private placement tranche.
Positive interim phase 2 CALLIPER data: vidofludimus calcium reduced NfL in PMS; top-line data expected April 2025.
Phase 3 ENSURE interim futility analysis expected late 2024; first read-out Q2 2026.
New US patents granted for vidofludimus calcium dosing regimens, providing protection into 2041.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IMMUNIC, INC. reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

Immunic , Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-24-000257

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.